AChE

Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were...


There is general consensus about the large and persuasive body of evidence that statins are effective and safe in reducing...


The FDA ( U.S. Food and Drug Administration ) has approved Siliq ( Brodalumab ) to treat adults with moderate-to-severe...



The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for the...


The U.S. Food and Drug Administration ( FDA ) has approved Ocrevus ( Ocrelizumab ) as the first and only...


Amyotrophic lateral sclerosis ( ALS ) is a rapidly progressing neurodegenerative disease that is characterized by motor neuron loss and...


Results from two phase 3 studies of the Tezacaftor ( VX-661 ) / Ivacaftor combination treatment that showed statistically significant...


The European Commission ( EC ) has granted Conditional Marketing Authorisation for Natpar ( rhPTH [ 1-84 ] ), the...


Multiple sclerosis ( MS ) is increasingly being viewed and studied not only as an immune-mediated demyelinating and neurodegenerative disease...


As the Zika virus continues to spread globally, new evidence has emerged about the virus's potentially detrimental effects on the...


The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In...


Updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( MPDL3280A )...


The FDA ( Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) for the treatment of people with...


Verubecestat is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 ( BACE1 )...


Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Researchers have assessed...


Results from a phase 2 clinical trial investigating Palovarotene for the treatment of fibrodysplasia ossificans progressiva ( FOP ) were...


Results from the phase II study of WT1 first-in-class immunotherapeutic anti-cancer treatment in multiple myeloma patients following autologous stem cell...


The phase 3 GAUSS-3 ( Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 ) trial evaluating Evolocumab...


The FDA ( U.S. Food and Drug Administration ) has approved Adynovate [ antihemophilic factor ( recombinant), PEGylated ], an...